10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
21.37
-0.91 (-4.08%)
At close: Apr 28, 2026, 4:00 PM EDT
21.46
+0.09 (0.42%)
After-hours: Apr 28, 2026, 7:46 PM EDT
10x Genomics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for 10x Genomics stock have an average target of 20.25, with a low estimate of 6.50 and a high estimate of 32. The average target predicts a decrease of -5.24% from the current stock price of 21.37.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for 10x Genomics stock from 15 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 2 | 2 | 3 | 3 |
| Hold | 6 | 8 | 9 | 9 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 13 | 13 | 14 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $22 → $32 | Strong Buy | Maintains | $22 → $32 | +49.74% | Apr 20, 2026 |
| B of A Securities | B of A Securities | Hold Maintains $21 → $30 | Hold | Maintains | $21 → $30 | +40.38% | Apr 20, 2026 |
| Barclays | Barclays | Buy Maintains $22 → $30 | Buy | Maintains | $22 → $30 | +40.38% | Apr 14, 2026 |
| Citigroup | Citigroup | Hold Maintains $18 → $24 | Hold | Maintains | $18 → $24 | +12.31% | Apr 7, 2026 |
| William Blair | William Blair | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Mar 31, 2026 |
Financial Forecast
Revenue This Year
619.75M
from 642.82M
Decreased by -3.59%
Revenue Next Year
665.19M
from 619.75M
Increased by 7.33%
EPS This Year
-0.98
from -0.35
EPS Next Year
-0.76
from -0.98
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 655.2M | 721.4M | |||||
| Avg | 619.8M | 665.2M | |||||
| Low | 596.1M | 622.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 1.9% | 16.4% | |||||
| Avg | -3.6% | 7.3% | |||||
| Low | -7.3% | 0.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -0.72 | -0.23 | ||||
| Avg | -0.98 | -0.76 | ||||
| Low | -1.20 | -0.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.